Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2021 07:50 ET | Source: Small Pharma Inc.

Small Pharma to Attend Upcoming Healthcare Conferences in November 2021

LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is...
November 01, 2021 17:28 ET | Source: Small Pharma Inc.

Small Pharma Reports Second Quarter Highlights

Company advances ongoing clinical trials with Phase I completed and dosing initiated in Phase IIa trial for lead product candidate, SPL026, a DMT-assisted therapy for the treatment of Major Depressive...
October 25, 2021 07:50 ET | Source: Small Pharma Inc.

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies,...
October 21, 2021 07:50 ET | Source: Small Pharma Inc.

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

LONDON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is...
October 20, 2021 07:50 ET | Source: Small Pharma Inc.

Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

LONDON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is...
October 19, 2021 07:50 ET | Source: Small Pharma Inc.

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

Phase IIa to explore the effectiveness of DMT in combination with psychotherapy for the potential treatment of Major Depressive Disorder Program remains on track for topline results in H1 2022 ...
October 18, 2021 18:10 ET | Source: Small Pharma Inc.

Small Pharma to Restate Financial Statements to Reflect IFRS Fair Value of Convertible Notes and Share Options

LONDON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced...
October 07, 2021 07:50 ET | Source: Small Pharma Inc.

Small Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

LONDON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021. Mr. Rands will discuss Small Pharma’s progress in...
September 21, 2021 07:50 ET | Source: Small Pharma Inc.

Small Pharma Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy

Small Pharma’s DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers Dataset generated from Phase I enables the selection of the optimal dose of...
September 20, 2021 07:50 ET | Source: Small Pharma Inc.

Small Pharma Included in AdvisorShares® Newly Launched Psychedelics ETF

LONDON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces today...